Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment.
Future Oncol
; 18(25): 2843-2856, 2022 Aug.
Article
en En
| MEDLINE
| ID: mdl-35801416
When deciding which treatment patients with relapsed or refractory multiple myeloma should receive, physicians have to weigh the benefits of each treatment against the risk of side effects. This study required physicians to complete a survey on aspects involved in their treatment decisions and identified those of highest importance. Physicians chose patient survival as the most important factor and minimization of side effects as less important considerations. Reducing patients' risk of developing corneal conditions or low platelet (a type of blood cell) count were of equal importance to doctors. Understanding physicians' treatment preferences and the reasons behind them will help identify gaps in education about new therapies as they become available.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Médicos
/
Mieloma Múltiple
Tipo de estudio:
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido